1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Neurotrope BioSciences moves forward with novel Alzheimer's candidate

 
• By Alexandra Shimmings

Alzheimer's disease start up Neurotrope BioSciences is to proceed to Phase IIb studies of its lead product bryostatin after positive top-line safety data from a Phase IIa trial.

Alzheimer's disease start up Neurotrope BioSciences is to proceed to Phase IIb studies of its lead product bryostatin after positive top-line safety data from a Phase IIa trial.

The product acts by modulating protein kinase C epsilon (PKCe), activation of which, the company says, has been shown to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.